Clinical Trials on Extensive-stage Small-cell Lung Cancer

Total 8026 results

Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

China, Georgia, Poland, Russian Federation, Turkey, Ukraine
Georgetown University
Bristol-Myers Squibb; Advanced Accelerator Applications

Completed

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Haihe Biopharma Co., Ltd.

Unknown

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Extensive-stage Small Cell Lung Cancer

China
Fudan University

Unknown

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

Extensive Stage Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Celgene

Completed

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
Hellenic Cooperative Oncology Group

Recruiting

Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer (DRIVE)

Small-cell Lung Cancer | Extensive-stage Small-cell Lung Cancer

Greece
National Cancer Institute (NCI)

Completed

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
iOMEDICO AG
Roche Pharma AG

Completed

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (CHAPLIN)

Extensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Extensive Stage Small Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
Universität des Saarlandes

Recruiting

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Extensive-stage Small-cell Lung Cancer

Germany
Baohui Han

Not yet recruiting

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Extensive-stage Small-cell Lung Cancer

China
Yunpeng Liu

Unknown

Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic

Extensive Stage Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...
Thoraxklinik-Heidelberg gGmbH

Active, not recruiting

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (TREASURE)

Thoracic Radiotherapy | Small Cell Lung Cancer Extensive Stage

Germany, Austria
Hansoh BioMedical R&D Company

Withdrawn

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Cancer Institute and Hospital, Chinese Academy...

Unknown

PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (PICARES)

Extensive-stage Small Cell Lung Cancer | Radiotherapy | Immunotherapy

China
BioNTech SE

Active, not recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Solid Tumor | Extensive-stage Small Cell Lung Cancer

United States, Spain, United Kingdom, Germany
Vanderbilt-Ingram Cancer Center
Genentech, Inc.

Recruiting

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TESSERACT)

Stage IV Lung Cancer | Extensive Stage Lung Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer

Tobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

United States
Kentuckiana Cancer Institute

Terminated

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Extensive Stage Unresectable

United States
G1 Therapeutics, Inc.

Recruiting

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer

Spain, Greece, Turkey, Poland, Georgia, Austria, Belgium, Bulgaria, Germany, Hungary
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage II Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage I Pancreatic Cancer | Stage II Non-small Cell Lung Cancer | Stage III Colon Cancer and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell Carcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Terminated

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
University of Alabama at Birmingham
National Comprehensive Cancer Network

Completed

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Extensive Stage Lung Cancer | Chemonaive

United States
City of Hope Medical Center
Addario Lung Cancer Medical Institute

Withdrawn

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Carcinoma

United States
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
University of California, Davis
Novartis

Completed

Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Extensive Stage Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Extensive Stage Small Cell Lung Cancer

United States
Henan Cancer Hospital

Recruiting

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

SCLC, Extensive Stage

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Henan Cancer Hospital

Recruiting

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

SCLC, Extensive Stage

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditions

United States
Wake Forest University Health Sciences

Withdrawn

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Lung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...

United States

Clinical Trials on Extensive-stage Small-cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations